Program
vilanterol
Also written as “GW642444”, “FF/UMEC/VI” and “Vilanterol”.
Its studies are mostly in Pulmonary Disease, Chronic Obstructive · Asthma, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 791 open or running | phase 4since Oct 4, 2013 | Jun 29, 2006 | Jan 26, 2027phase 3 · NCT05757102 |
| Sandoz | 10 open or running | phase 3since Oct 15, 2025 | Oct 15, 2025 | none ahead |
Also a collaborator on its studies: parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 44 studies since May 6, 2010.
- May 14, 2015Phase 3 study in AsthmaGlaxoSmithKline · NCT02446418 · 423 enrolled · France, Germany
- Jan 25, 2016Phase 1 study in Pulmonary Disease, Chronic ObstructiveGlaxoSmithKline · NCT02666287 · 48 enrolled · United Kingdom
- Mar 14, 2016Phase 2 study in AsthmaGlaxoSmithKline · NCT02712047 · 28 enrolled · New Zealand
- Mar 24, 2016Phase 4 study in AsthmaGlaxoSmithKline · NCT02730351 · 75 enrolled · United States, Canada
- Nov 30, 2017Phase 4 study in AsthmaGlaxoSmithKline · NCT03363191
- Dec 1, 2017Phase 3 study in AsthmaGlaxoSmithKline · NCT03376932
- Feb 2, 2018Phase 4 study in Pulmonary Disease, Chronic ObstructiveGlaxoSmithKline · NCT03467425 · 3,109 enrolled · Germany, Netherlands, Spain and more
- Mar 15, 20183 phase 4 studies in Pulmonary Disease, Chronic ObstructiveGlaxoSmithKline · NCT03474081, NCT03478696, NCT03478683
- May 13, 2019Phase 4 study in Pulmonary Disease, Chronic ObstructiveGlaxoSmithKline · NCT03949842 · United States
- Jun 2, 2021Phase 3 study in AsthmaGlaxoSmithKline · NCT04937387 · 359 enrolled · China
- Jun 6, 2021Phase 4 study in Pulmonary Disease, Chronic ObstructiveGlaxoSmithKline · NCT04923347 · 229 enrolled · India
- Sep 7, 2022Phase 4 study in Pulmonary Disease, Chronic ObstructiveGlaxoSmithKline · NCT05535972 · 463 enrolled · China
- Feb 24, 2023Phase 3 study in AsthmaGlaxoSmithKline · NCT05757102 · 138 enrolled · United States, Argentina, Australia and more
- Oct 15, 2025Sandoz's first study: phase 3 study in RespiratoryNew to SandozSandoz · NCT07223294
Ahead
- Jan 26, 2027Primary completion: phase 3 study in AsthmaGlaxoSmithKline · NCT05757102
TargetBeta
“Beta-2 adrenergic receptor agonist”ChEMBL 37, by rule
Other programs on ADRB2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Timololrule | AbbVie | phase 4 | 27 |
| Epinephrinerule | nasus-pharma | phase 4 | 17 |
| TQC3927 | Sino Biopharmaceutical | phase 2 | 3 |
| TQC3302 | Sino Biopharmaceutical | phase 1 | 1 |
Studies
The newest 60 of 80 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07223294Respiratory | 3 | Withdrawn | Sandoz | Apr 21, 2026 | 0 |
| NCT05757102Asthma · United States, Argentina, Australia and more | 3 | Active, not recruiting | GlaxoSmithKline | Jan 26, 2027 | 138 |
| NCT05535972Pulmonary Disease, Chronic Obstructive · China | 4 | Completed | GlaxoSmithKline | Sep 25, 2023 | 463 |
| NCT04923347Pulmonary Disease, Chronic Obstructive · India | 4 | Completed | GlaxoSmithKline | Mar 14, 2024 | 229 |
| NCT04937387Asthma · China | 3 | Completed | GlaxoSmithKline | Aug 5, 2024 | 359 |
| NCT03949842Pulmonary Disease, Chronic Obstructive · United States | 4 | Withdrawn | GlaxoSmithKline | Nov 30, 2022 | 0 |
| NCT03478696Pulmonary Disease, Chronic Obstructive · United States, Czechia, Germany | 4 | Completed | GlaxoSmithKline | Mar 18, 2019 | 732 |
| NCT03478683Pulmonary Disease, Chronic Obstructive · United States, Czechia, Germany and more | 4 | Completed | GlaxoSmithKline | Mar 14, 2019 | 729 |
| NCT03474081Pulmonary Disease, Chronic Obstructive · United States, Poland, Russian Federation | 4 | Completed | GlaxoSmithKline | Jul 17, 2019 | 800 |
| NCT03467425Pulmonary Disease, Chronic Obstructive · Germany, Netherlands, Spain and more | 4 | Completed | GlaxoSmithKline | Oct 10, 2019 | 3,109 |
| NCT03376932Asthma | 3 | Withdrawn | GlaxoSmithKline | Feb 3, 2021 | 0 |
| NCT03363191Asthma | 4 | Withdrawn | GlaxoSmithKline | May 29, 2019 | 0 |
| NCT02730351Asthma · United States, Canada | 4 | Completed | GlaxoSmithKline | Feb 3, 2017 | 75 |
| NCT02712047Asthma · New Zealand | 2 | Completed | GlaxoSmithKline | Feb 21, 2017 | 28 |
| NCT02666287Pulmonary Disease, Chronic Obstructive · United Kingdom | 1 | Completed | GlaxoSmithKline | Jun 3, 2016 | 48 |
| NCT02446418Asthma · France, Germany | 3 | Completed | GlaxoSmithKline | Jul 20, 2017 | 423 |
| NCT02105974Pulmonary Disease, Chronic Obstructive · United States, Bulgaria, Germany and more | 3 | Completed | GlaxoSmithKline | Jul 8, 2015 | 1,621 |
| NCT02094937Asthma · Japan | 3 | Completed | GlaxoSmithKline | Aug 28, 2015 | 430 |
| NCT01957150Pulmonary Disease, Chronic Obstructive · United States, Canada, Germany and more | 4 | Completed | GlaxoSmithKline | Mar 26, 2018 | 283 |
| NCT01899742Pulmonary Disease, Chronic Obstructive · United States, Argentina, Estonia and more | 3 | Completed | GlaxoSmithKline | Jul 22, 2015 | 497 |
| NCT01822899Pulmonary Disease, Chronic Obstructive · Czechia, Denmark, Germany and more | 3 | Completed | GlaxoSmithKline | Oct 1, 2013 | 717 |
| NCT01817764Pulmonary Disease, Chronic Obstructive · United States, Argentina, Chile and more | 3 | Completed | GlaxoSmithKline | Oct 1, 2013 | 707 |
| NCT01777334Pulmonary Disease, Chronic Obstructive · United States, Argentina, Bulgaria and more | 3 | Completed | GlaxoSmithKline | Sep 24, 2013 | 905 |
| NCT01706198Asthma · United Kingdom | 3 | Completed | GlaxoSmithKline | Dec 1, 2016 | 4,233 |
| NCT01686633Asthma · United States, Argentina, Chile and more | 3 | Completed | GlaxoSmithKline | Oct 1, 2013 | 1,040 |
| NCT01711463Asthma · China | 1 | Completed | GlaxoSmithKline | Jun 4, 2013 | 16 |
| NCT01691885Pulmonary Disease, Chronic Obstructive · United Kingdom | 3 | Completed | GlaxoSmithKline | Jul 2014 | 45 |
| NCT01627327Pulmonary Disease, Chronic Obstructive · United States, Canada, Czechia and more | 3 | Completed | GlaxoSmithKline | Dec 1, 2012 | 623 |
| NCT01571999Pulmonary Disease, Chronic Obstructive · Czechia, Hungary | 1 | Completed | GlaxoSmithKline | Jun 22, 2012 | 17 |
| NCT01577680Pulmonary Disease, Chronic Obstructive · Hungary, Slovakia | 1 | Completed | GlaxoSmithKline | Jun 29, 2012 | 18 |
| NCT01573767Asthma · United States, Argentina, Chile and more | 2 | Completed | GlaxoSmithKline | Apr 2014 | 463 |
| NCT01551758Pulmonary Disease, Chronic Obstructive · United Kingdom | 3 | Completed | GlaxoSmithKline | Nov 24, 2015 | 2,802 |
| NCT01498679Asthma · China, Korea, Republic of, Philippines | 3 | Completed | GlaxoSmithKline | Jul 2013 | 311 |
| NCT01498653Asthma · China, Korea, Republic of, Philippines | 3 | Completed | GlaxoSmithKline | Feb 2013 | 313 |
| NCT01485445Asthma · Germany | 1 | Completed | GlaxoSmithKline | Mar 12, 2012 | 30 |
| NCT01453023Asthma · United States | 2 | Completed | GlaxoSmithKline | Jun 2012 | 26 |
| NCT01435902Asthma | 3 | Withdrawn | GlaxoSmithKline | Aug 2012 | 0 |
| NCT01453296Asthma · United States | 2 | Completed | GlaxoSmithKline | Apr 2011 | 28 |
| NCT01395888Pulmonary Disease, Chronic Obstructive · Argentina, France, Germany and more | 3 | Completed | GlaxoSmithKline | Aug 1, 2012 | 260 |
| NCT01376388Pulmonary Disease, Chronic Obstructive · Japan | 3 | Completed | GlaxoSmithKline | Dec 2012 | 131 |
| NCT01376245Pulmonary Disease, Chronic Obstructive · China, Korea, Republic of, Philippines and more | 3 | Completed | GlaxoSmithKline | Sep 2012 | 646 |
| NCT01328444Pulmonary Disease, Chronic Obstructive · United States, Bulgaria, Estonia and more | 3 | Completed | GlaxoSmithKline | Jun 1, 2012 | 349 |
| NCT01336608Pulmonary Disease, Chronic Obstructive · United States, Germany, Korea, Republic of and more | 3 | Completed | GlaxoSmithKline | Nov 4, 2014 | 446 |
| NCT01323660Pulmonary Disease, Chronic Obstructive · United States, Canada, Czechia and more | 3 | Completed | GlaxoSmithKline | Jul 1, 2012 | 307 |
| NCT01316913Pulmonary Disease, Chronic Obstructive · United States, Argentina, Australia and more | 3 | Completed | GlaxoSmithKline | Apr 2012 | 872 |
| NCT01316900Pulmonary Disease, Chronic Obstructive · United States, France, Germany and more | 3 | Completed | GlaxoSmithKline | Apr 1, 2012 | 846 |
| NCT01313637Pulmonary Disease, Chronic Obstructive · United States, Belgium, Denmark and more | 3 | Completed | GlaxoSmithKline | Mar 1, 2012 | 1,493 |
| NCT01313676Pulmonary Disease, Chronic Obstructive · United States, Argentina, Australia and more | 3 | Completed | GlaxoSmithKline | Jul 15, 2015 | 16,568 |
| NCT01244984Asthma · Japan | 3 | Completed | GlaxoSmithKline | Jan 2012 | 243 |
| NCT01213849Asthma · United Kingdom | 1 | Completed | GlaxoSmithKline | Nov 25, 2010 | 24 |
| NCT01209026Asthma · United Kingdom | 1 | Completed | GlaxoSmithKline | Jan 4, 2011 | 85 |
| NCT01192191Pulmonary Disease, Chronic Obstructive · Japan | 3 | Completed | GlaxoSmithKline | Jan 2012 | 187 |
| NCT01181895Asthma · United States, Germany, Peru and more | 3 | Completed | GlaxoSmithKline | Aug 1, 2011 | 348 |
| NCT01165138Asthma · United States, Germany, Japan and more | 3 | Completed | GlaxoSmithKline | Oct 1, 2011 | 612 |
| NCT01165125Asthma · United Kingdom | 1 | Completed | GlaxoSmithKline | Aug 28, 2010 | 18 |
| NCT01299558Asthma · Australia | 1 | Completed | GlaxoSmithKline | Jul 15, 2010 | 16 |
| NCT01147848Asthma · United States, Argentina, Chile and more | 3 | Completed | GlaxoSmithKline | Jul 2011 | 810 |
| NCT01134042Asthma · United States, Germany, Japan and more | 3 | Completed | GlaxoSmithKline | Oct 2011 | 587 |
| NCT01128569Asthma · Germany, New Zealand, United Kingdom | 2 | Completed | GlaxoSmithKline | Oct 2010 | 52 |
| NCT01286831Pulmonary Disease, Chronic Obstructive · Netherlands | 1 | Completed | GlaxoSmithKline | Jul 9, 2010 | 6 |
How it is read
Names in the registry
- “GW642444”, 15 entries
- “FF/UMEC/VI”, 9 entries
- “Vilanterol”, 8 entries
- “Fluticasone Furoate/Vilanterol”, 7 entries
- “FF/GW642444 Inhalation Powder”, 4 entries
Codes read as this program: GW642444.
Conditions, from the studies’ own filings
- Pulmonary Disease, Chronic Obstructive, 46 studies
- Asthma, 33 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.